[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#2d81b5″ locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” header_font=”Montserrat|600|||||||” header_text_color=”#FFFFFF” header_font_size=”3rem” header_line_height=”3.5rem” header_font_size_tablet=”2rem” header_font_size_phone=”” header_font_size_last_edited=”on|tablet” header_line_height_tablet=”2.5rem” header_line_height_phone=”” header_line_height_last_edited=”on|tablet” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.3″ _module_preset=”default” text_font=”||||||||” text_font_size=”1.1rem” text_line_height=”1.75rem” header_2_font=”Montserrat|500|||||||” header_2_font_size=”1.3rem” header_2_line_height=”1.4em” header_4_line_height=”1.5em” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.27.3″ _module_preset=”default” text_font=”||||||||” text_font_size=”1.1rem” text_line_height=”1.75rem” link_font=”Montserrat|500|||on||||” link_text_color=”#2d81b5″ link_font_size=”1rem” header_2_font=”|600|||||||” header_2_font_size=”1.3rem” custom_margin=”||||false|false” custom_padding=”||||false|false” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
MEDIA ALERT: WOBURN, MA, March 14, 2025<\/strong>\u00a0<\/span>\u2013\u00a0<\/span>Azurity Pharmaceuticals<\/a><\/span>\u00a0(\u201cAzurity\u201d) announced today the successful completion of its acquisition of Covis Group S.\u00e0 r.l. \u00a0(\u201cCovis\u201d) from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity.<\/p>\n This strategic acquisition reinforces Azurity\u2019s leadership in branded pharmaceuticals, harnessing the complementary strengths of both companies across multiple complex dosage forms and therapeutic areas. By combining expertise and resources, Azurity strengthens its ability to deliver medicines to overlooked patients on a global scale.<\/p>\n Strategic Benefits of the Acquisition:<\/strong><\/p>\n \u201cWe are excited to welcome Covis Pharma to Azurity,\u201d said\u00a0<\/span>Ronald Scarboro, CEO of Azurity<\/strong>. \u201cThe efforts of colleagues at both companies, their devotion to overlooked patients, and our culture of execution have brought us together to build this unique, highly differentiated pharmaceutical company. I look forward to all that we will accomplish as we grow globally and embrace new opportunities, driven by our purpose.\u201d \u201cI am delighted that Azurity recognized the accomplishments and potential of Covis, and am thankful for the tireless efforts of Covis colleagues in support of patients that benefit from the company\u2019s products,\u201d said\u00a0<\/span>Rajiv De Silva, Chairman of the Board of Covis<\/strong>. \u201cI am confident that the two companies will be able to untap each other\u2019s highly complementary capabilities to accelerate development and commercialization of necessary medicines to underserved patients.\u201d<\/p>\n \u201cQHP Capital is proud to support Azurity in this acquisition, which aligns with our commitment to investing in life sciences and healthcare innovations,\u201d said\u00a0<\/span>Jeff Edwards, Partner at QHP Capital, the majority owner of Azurity.<\/strong>\u00a0\u201cIt has been our privilege to support and enable Azurity from a small, limited product, US-only company at the start of our investment in 2018 to the global, large, diversified portfolio, high-growth company it is today. We are committed to further enabling Azurity for the significant growth its team is well positioned to execute.\u201d<\/p>\n Goldman Sachs served as financial advisor and Eversheds Sutherland and White & Case served as legal advisors to Azurity. Guggenheim Securities served as financial advisor to Covis and Reed Smith and A&O Shearman served as legal advisors to Covis.<\/p>\n<\/div>\n<\/div>\n About Azurity Pharmaceuticals:<\/strong><\/p>\n Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity\u2019s\u00a0 global footprint is over 50 countries, with a diversified portfolio of 30+ marketed brands spanning ten dosage forms and nine key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. For more information, visit\u00a0<\/span>www.azurity.com<\/a>.<\/p>\n About QHP Capital:<\/strong><\/p>\n QHP Capital is an investor in technology and services companies in the life sciences, medical technology, and healthcare sectors. QHP has built an investment platform to provide strategic capital and industry expertise in partnership with strong management teams. The investment team consists of seasoned investment and operational professionals with significant investment experience and deep life science, medical technology, and healthcare expertise. QHP benefits from an extensive network of industry experts that assist in identifying, analyzing, and growing QHP\u2019s portfolio companies. For more information, please visit\u00a0www.qhpcapital.com<\/a><\/span>.<\/p>\n<\/div>\n<\/div>\n Disclosure notice:\u00a0<\/span><\/strong>Azurity and QHP undertake no obligation to update or revise any forward-looking statements contained in this release as a result of new information, future events, or evolving circumstances.<\/p>\n Contact: Azurity Pharmaceuticals Media Relations<\/p>\n\n
<\/span><\/p>\n